4 completed. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Rheumatoid Arthritis, Systemic Juvenile: new trials by email Literature Review of Rheumatoid Arthritis, Systemic Juvenile trials Research Report on Rheumatoid Arthritis, Systemic Juvenile
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA Canakinumab - Systemic Juvenile Idiopathic Arthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 19 | 2015-05-07 | 2019-09-13 |
| ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab ACZ885 150 mg (Canakinumab) - Systemic Juvenile Idiopathic Arthritis (SJIA) | Phase 3 | Completed | Novartis Pharmaceuticals | 182 | 2014-11-17 | 2019-07-09 |
| A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies canakinumab - Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | Phase 3 | Completed | Novartis Pharmaceuticals | 31 | 2014-11-03 | 2020-05-19 |
| Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults Rilonacept - Juvenile Idiopathic Arthritis | Phase 2 | Completed | Montefiore Medical Center | 71 | 2008-11-01 | 2015-12-11 |
Arthritis, Juvenile (4) · Arthralgia (3) · Bronchiolitis Obliterans Syndrome (3) · Cryopyrin-Associated Periodic Syndromes (1) · Mevalonate Kinase Deficiency (1)
Arthritis (4) · Autoimmune Diseases (4) · Connective Tissue Diseases (4) · Immune System Diseases (4) · Joint Diseases (4) · Musculoskeletal Diseases (4) · Rheumatic Diseases (4) · Skin and Connective Tissue Diseases (4) · Bronchial Diseases (3) · Bronchiolitis (3) · Bronchiolitis Obliterans (3) · Bronchitis (3) · Graft vs Host Disease (3) · Lung Diseases (3) · Lung Diseases, Obstructive (3)
canakinumab (3) · rilonacept (1)
Novartis Pharmaceuticals (3) · Montefiore Medical Center (1)
France (2) · United States (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1)
2014 (1), 2018 (1), 268200700015C-2-0-0 (1)